1. Home
  2. CNTN vs CHEC Comparison

CNTN vs CHEC Comparison

Compare CNTN & CHEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$2.84

Market Cap

185.3M

Sector

Health Care

ML Signal

N/A

CHEC

Chenghe Acquisition III Co. Class A Ordinary Share

N/A

Current Price

$10.18

Market Cap

175.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CNTN
CHEC
Founded
2017
2024
Country
United States
Singapore
Employees
12
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.3M
175.5M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
CNTN
CHEC
Price
$2.84
$10.18
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.3M
42.9K
Earning Date
05-13-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.14
$9.91
52 Week High
$5.27
$10.56

Technical Indicators

Market Signals
Indicator
CNTN
CHEC
Relative Strength Index (RSI) 46.09 66.02
Support Level $2.14 $10.02
Resistance Level $3.80 $10.47
Average True Range (ATR) 0.31 0.00
MACD -0.01 -0.00
Stochastic Oscillator 19.83 100.00

Price Performance

Historical Comparison
CNTN
CHEC

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About CHEC Chenghe Acquisition III Co. Class A Ordinary Share

Chenghe Acquisition III Co is blank check company.

Share on Social Networks: